Kevin Patrick Danahy net worth and biography

Kevin Danahy Biography and Net Worth

CEO of Pulse Biosciences

Kevin Danahy was appointed Chief Commercial Officer in May 2024, having previously served as the Company’s President and Chief Executive Officer since September 2022. Mr. Danahy has more than 20 years of senior leadership experience building and leading strategic commercial organizations for medical technology companies. Prior to joining Pulse Biosciences, Mr. Danahy served as President of Solmetex, driving revenue growth for the company through the implementation of innovative and scalable solutions, while overseeing strategy, sales, marketing, operations, engineering, and service efforts. Previously, at Zimmer Biomet, Mr. Danahy held roles of increasing responsibility, most recently as Vice President of Global Emerging Technologies and Specialty Sales. Before his time at Zimmer, Mr. Danahy served as Senior Director at Intuitive Surgical, where he successfully transformed the sales leadership training program. Early in his career, he served in commercial leadership roles at both Medtronic and Johnson & Johnson. Mr. Danahy holds a Master’s of Science from Tufts University.

What is Kevin Patrick Danahy's net worth?: The estimated net worth of Kevin Patrick Danahy is at least $546,559.01 as of November 16th, 2023. Mr. Danahy owns 35,887 shares of Pulse Biosciences stock worth more than $546,559 as of April 7th. This net worth approximation does not reflect any other investments that Mr. Danahy may own. Learn More about Kevin Patrick Danahy's net worth.
How do I contact Kevin Patrick Danahy?: The corporate mailing address for Mr. Danahy and other Pulse Biosciences executives is 3957 POINT EDEN WAY, HAYWARD CA, 94545. Pulse Biosciences can also be reached via phone at (510) 906-4600 and via email at ir@pulsebiosciences.com. Learn More on Kevin Patrick Danahy's contact information.
Has Kevin Patrick Danahy been buying or selling shares of Pulse Biosciences?: Kevin Patrick Danahy has not been actively trading shares of Pulse Biosciences during the last quarter. Most recently, on Thursday, November 16th, Kevin Patrick Danahy bought 5,393 shares of Pulse Biosciences stock. The stock was acquired at an average cost of $6.52 per share, with a total value of $35,162.36. Following the completion of the transaction, the chief executive officer now directly owns 35,887 shares of the company's stock, valued at $233,983.24. Learn More on Kevin Patrick Danahy's trading history.
Who are Pulse Biosciences' active insiders?: Pulse Biosciences' insider roster includes Kevin Danahy (CEO), Robert Duggan (Co-Chairman of the Board of Directors), Mitchell Levinson (Insider), and Mitchell Levinson (Insider). Learn More on Pulse Biosciences' active insiders.
Are insiders buying or selling shares of Pulse Biosciences?: In the last twelve months, Pulse Biosciences insiders bought shares 3 times. They purchased a total of 121,310 shares worth more than $2,007,434.98. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 50,000 shares worth more than $871,000.00. The most recent insider tranaction occured on December, 13th when Director Robert W Duggan bought 55,256 shares worth more than $949,298.08. Insiders at Pulse Biosciences own 71.5% of the company. Learn More about insider trades at Pulse Biosciences.
Information on this page was last updated on 12/13/2024.

Kevin Patrick Danahy Insider Trading History at Pulse Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/16/2023	Buy	5,393	$6.52	$35,162.36	35,887
9/30/2022	Buy	6,500	$2.30	$14,950.00	6,500

Kevin Patrick Danahy Buying and Selling Activity at Pulse Biosciences

Pulse Biosciences Company Overview

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Today's Range

Now: $15.23

$13.80

$16.12

50 Day Range

MA: $18.54

$14.53

$24.56

2 Week Range

Now: $15.23

$6.60

$25.00

Volume

49,087 shs

Average Volume

197,151 shs

Market Capitalization

$1.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87